Opportunities and challenges in vaccine delivery

被引:14
作者
Carstens, Myrra G. [1 ]
机构
[1] Leiden Univ, Fac Sci, Div Drug Delivery Technol, LACDR, NL-2333 CC Leiden, Netherlands
关键词
Vaccine delivery; EUFEPS workshop report; Adjuvant technology; Antigen formulation; Needle-free delivery; Particulate delivery systems; MICRONEEDLE ARRAYS; DNA VACCINATION; RATIONAL DESIGN; HUMAN SKIN; ADJUVANT; MICROPARTICLES; IMMUNOGENICITY; PROTECTION; LECTINS; ANTIGEN;
D O I
10.1016/j.ejps.2008.11.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This report is a distillation of the workshop 'Opportunities and Challenges in Vaccine Delivery', organised by EUFEPS/FIP and co-sponsored by AAPS and CRS, in Archamps, France, September 2008. The aim of this workshop was to bridge knowledge gaps between the different disciplines involved in the delivery of vaccines. Here, key challenges include target identification, mapping the needs and target population, the development and harmonisation of predictive read-out systems and surrogate markers for protection, and improving antigen immunogenicity, delivery and stability. The workshop underlined the need and possibilities of a multidisciplinary approach to meet these challenges. This involves increasing our understanding of immunological mechanisms, the development of advanced delivery systems and adjuvant technologies, and insight into the regulatory guidelines and target population. Based upon this knowledge, future vaccinology can increasingly focus on rational design of antigens, adjuvants and delivery systems, which will lead to new and improved vaccines. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:605 / 608
页数:4
相关论文
共 34 条
[1]   Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements [J].
Agger, Else Marie ;
Rosenkrands, Ida ;
Hansen, Jon ;
Brahimi, Karima ;
Vandahl, Brian S. ;
Aagaard, Claus ;
Werninghaus, Kerstin ;
Kirschning, Carsten ;
Lang, Roland ;
Christensen, Dennis ;
Theisen, Michael ;
Follmann, Frank ;
Andersen, Peter .
PLOS ONE, 2008, 3 (09)
[2]   N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination:: Biological properties and immunogenicity in a mouse model [J].
Amidi, Maryam ;
Romeijn, Stefan G. ;
Verhoef, J. Coos ;
Junginger, Hans E. ;
Bungener, Laura ;
Huckriede, Anke ;
Crommelin, Daan J. A. ;
Jiskoot, Wim .
VACCINE, 2007, 25 (01) :144-153
[3]   Cross-protection by MF59™-adjuvanted influenza vaccine:: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses [J].
Ansaldi, Filippo ;
Bacilieri, Sabrina ;
Durando, Paolo ;
Sticchi, Laura ;
Valle, Laura ;
Montomoli, Ernanuele ;
Icardi, Giancarlo ;
Gasparini, Roberto ;
Crovari, Pietro .
VACCINE, 2008, 26 (12) :1525-1529
[4]   Opinion - Therapeutic vaccination for chronic diseases: a new class of drugs in sight [J].
Bachmann, MF ;
Dyer, MR .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (01) :81-88A
[5]   In vivo assessment of safety of microneedle arrays in human skin [J].
Bal, Suzanne M. ;
Caussin, Julia ;
Pavel, Stan ;
Bouwstra, Joke A. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 35 (03) :193-202
[6]   Pulmonary DNA vaccination: Concepts, possibilities and perspectives [J].
Bivas-Benita, M ;
Ottenhoff, THM ;
Junginger, HE ;
Borchard, G .
JOURNAL OF CONTROLLED RELEASE, 2005, 107 (01) :1-29
[7]   Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis [J].
Bivas-Benita, M ;
van Meijgaarden, KE ;
Franken, KLMC ;
Junginger, HE ;
Borchard, G ;
Ottenhoff, THM ;
Geluk, A .
VACCINE, 2004, 22 (13-14) :1609-1615
[8]   Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems [J].
Friede, M ;
Aguado, MT .
ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (03) :325-331
[9]   Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization [J].
Glueck, R .
VACCINE, 2001, 20 :S42-S44
[10]   A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles [J].
Gomez, Julia M. Martinez ;
Fischer, Stefan ;
Csaba, Noemi ;
Kuendig, Thomas M. ;
Merkle, Hans P. ;
Gander, Bruno ;
Johansen, Pal .
PHARMACEUTICAL RESEARCH, 2007, 24 (10) :1927-1935